BioNTech SE ADR buy MoneyMoney
Start price
13.07.20
/
0%
€67.74
Target price
04.11.21
€250.00
Performance (%)
254.74%
End price
05.11.21
€240.30
Summary
This prediction ended on 05.11.21 with a price of €240.30. The BUY prediction by MoneyMoney for BioNTech SE ADR saw massive gains of 254.74%. MoneyMoney has a follow-up prediction for BioNTech SE ADR where he still thinks BioNTech SE ADR is a Buy.Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
BioNTech SE ADR | 7.896% | 7.896% | 243.124% | - |
iShares Core DAX® | -0.922% | -1.078% | 12.165% | 16.796% |
iShares Nasdaq 100 | 0.371% | -0.556% | 38.622% | 49.370% |
iShares Nikkei 225® | 2.224% | -2.825% | 19.015% | 4.643% |
iShares S&P 500 | -0.026% | -0.788% | 28.485% | 42.479% |
According to MoneyMoney what are the pros and cons of BioNTech SE ADR for the foreseeable future?
Pros
EBIT growth > 30% per year expected
Higher EBIT margin than peer group
Fair valuation
Differentiated customer and product portfolio
Valuable balance sheet
High Investments for future growth
Future proof or reliable business model
Capable Management
Innovative
Growths faster than the competition
Stable Large shareholder and/or long term investor
Revenue growth > 30% per year expected
Well known brand
Top 10 in its market
Could be worthwhile Investment >10% per year
Good culture
Strong uniques
positive Cash Flow expected
Sustainability is important
Good rating
Cons
Higher risks for its business
Significant cyclical dependencies
Low dividend yield expected
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Comments by MoneyMoney for this prediction
In the thread Trading Biontech SE
Die von MoneyMoney gewählte maximale Laufzeit wurde überschritten
Current prediction by MoneyMoney for BioNTech SE ADR
BioNTech SE ADR
Start price
Target price
Perf. (%)
€81.35
18.04.24
18.04.24
€100.00
18.04.25
18.04.25
5.96%
03.05.24
03.05.24
EBIT growth > 30% per year expected
Higher EBIT margin than peer group
Fair valuation
Higher risks for its business